Top

Published in:

01-12-2016 | Review

Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling

Authors: Assumpta C. Nwaneri, Lucien McBeth, Terry D. Hinds Jr

Published in: Discover Oncology | Issue 5-6/2016

Abstract

Prostate cancer (PC) is one of the leading causes of mortality amongst elderly men in the USA and is second only to lung cancer. African Americans (AA) are at an increased risk of developing PC and are more likely to die from the disease in comparison to Caucasian Americans (CA). Chromosomal alterations or genetic differences between AA and CA may account for the variances observed in PC progression. Importantly, mutations in the androgen receptor (AR) or the epidermal growth factor receptor (EGFR) may contribute to the disparity. Current studies are investigating the role of small nucleotide polymorphisms (SNPs) and microRNAs (miRNAs), which affect protein translation of the receptors by regulation of the 3′ untranslated region (UTR), which may enhance the progression of PC. However, these genetic differences have not been fully explored in prostates between the two ethnic groups. This review will highlight the current studies on the EGFR signaling pathway as well as the involvement of SNPs and miRNAs and relate them to variances observed in PC of AA and CA men. With an understanding of these differences, specific preventive and therapeutic strategies may be developed to target personalized medicine for prostate carcinogenesis.

CDC, C.f.D.C.a.P. Cancer among men. 2013; ; Available from: http://www.cdc.gov/cancer/dcpc/data/men.htm.

McNeal JE (1988) Normal histology of the prostate. Am J Surg Pathol 12(8):619–633CrossRefPubMed

McNeal JE (1981) The zonal anatomy of the prostate. Prostate 2(1):35–49CrossRefPubMed

UK, C.R. Types of Prostate Cancer. March 2014 [cited 2014 June 6]; Available from: http://www.cancerresearchuk.org/cancer-help/type/prostate-cancer/about/prostate-cancer-types

Society, A.C (2016) Cancer facts & figs. 2016. American Cancer Society, Atlanta, Ga

Shuch B et al. (2004) Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 22(23):4725–4729CrossRefPubMed

Muniyan S et al. (2015) ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cell Signal 27(11):2261–2271CrossRefPubMed

Ye D, Mendelsohn J, Fan Z (1999) Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5(8):2171–2177PubMed

Groenen LC, Nice EC, Burgess AW (1994) Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors 11(4):235–257CrossRefPubMed

10.

Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284(1):2–13CrossRefPubMed

11.

Lemmon MA et al. (1997) Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 16(2):281–294CrossRefPubMedPubMedCentral

12.

O’Brien L et al. (2015) Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab 26(4):212–220CrossRefPubMedPubMedCentral

13.

Hallberg B, Rayter SI, Downward J (1994) Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem 269(6):3913–3916PubMed

14.

Liebmann C (2001) Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 13(11):777–785CrossRefPubMed

15.

Gaestel M (2006) MAPKAP kinases—MKs—two’s company, three’s a crowd. Nat Rev Mol Cell Biol 7(2):120–130CrossRefPubMed

16.

Hill CS, Treisman R (1995) Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80(2):199–211CrossRefPubMed

17.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMed

18.

Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424–430CrossRefPubMed

19.

Blanco-Aparicio C et al. (2007) PTEN, more than the AKT pathway. Carcinogenesis 28(7):1379–1386CrossRefPubMed

20.

Sun H et al. (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 96(11):6199–6204CrossRefPubMedPubMedCentral

21.

Petrovics G et al. (2015) A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine 2(12):1957–1964CrossRefPubMedPubMedCentral

22.

Khani F et al. (2014) Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res 20(18):4925–4934CrossRefPubMedPubMedCentral

23.

Winter JL et al. (2007) Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med 131(5):767–772PubMed

24.

Rimawi MF et al. (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116(5):1234–1242CrossRefPubMedPubMedCentral

25.

de Muga S et al. (2010) Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod Pathol 23(5):703–712CrossRefPubMed

26.

Ross R et al. (1986) Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76(1):45–48PubMed

27.

Ellis L, Nyborg H (1992) Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 57(2):72–75CrossRefPubMed

28.

Gaston KE et al. (2003) Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170(3):990–993CrossRefPubMed

29.

Edwards A et al. (1992) Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12(2):241–253CrossRefPubMed

30.

Chamberlain NL, Driver ED, Miesfeld RL (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22(15):3181–3186CrossRefPubMedPubMedCentral

31.

Ingles SA et al. (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89(2):166–170CrossRefPubMed

32.

Platz EA et al. (1998) The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomark Prev 7(5):379–384

33.

Giovannucci E et al. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94(7):3320–3323CrossRefPubMedPubMedCentral

34.

Bennett CL et al. (2002) Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol 20(17):3599–3604CrossRefPubMed

35.

Sartor O, Zheng Q, Eastham JA (1999) Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 53(2):378–380CrossRefPubMed

36.

Irvine RA et al. (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55(9):1937–1940PubMed

37.

Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4):232–240CrossRefPubMed

38.

NCI, N.C.I. Prostate Cancer Treatment. 2013 December 12 2013 [cited 2014 January 20]; Available from: http://www.cancer.gov/cancertopics/pdq/treatment/prostate/Patient/page1.

39.

Vogelzang N, Scardino P, Shipley W, Debruyne F, Linehan M (2006) Comprehensive textbook of genitourinary oncology, 3rd edn. Lippincott Williams and Wilkins, Philadelphia

40.

Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2):276–308CrossRefPubMed

41.

Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23(32):8253–8261CrossRefPubMed

42.

Pignon JC et al. (2009) Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res 69(7):2941–2949CrossRefPubMed

43.

Kumar VL et al. (1998) Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. Cancer Lett 134(2):177–180CrossRefPubMed

44.

Gil-Diez de Medina S et al. (1998) Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 29(9):1005–1012CrossRefPubMed

45.

Pu YS et al. (2006) Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 71(6):751–760CrossRefPubMed

46.

Sherwood ER et al. (1998) Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77(6):855–861CrossRefPubMedPubMedCentral

47.

Gravina GL et al. (2011) Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. Prostate 71(14):1481–1491PubMed

48.

Bonaccorsi L et al. (2007) Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 38(1–2):51–66CrossRefPubMed

49.

Perez CA et al. (2010) The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 183(5):2062–2069CrossRefPubMedPubMedCentral

50.

Lin HY et al. (2013) SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness. PLoS One 8(4):e59688CrossRefPubMedPubMedCentral

51.

Amundadottir LT et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38(6):652–658CrossRefPubMed

52.

Freedman ML et al. (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 103(38):14068–14073CrossRefPubMedPubMedCentral

53.

Zheng SL et al. (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer prostate in Sweden study. Cancer Res 64(8):2918–2922CrossRefPubMed

54.

Xu J et al. (2010) Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA 107(5):2136–2140CrossRefPubMedPubMedCentral

55.

Alberts D et al. (2004) Safety and efficacy of dose-intensive oral vitamin a in subjects with sun-damaged skin. Clin Cancer Res 10(6):1875–1880CrossRefPubMed

56.

Vasudevan S, Tong Y, Steitz JA (2007) Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858):1931–1934CrossRefPubMed

57.

Tao J et al. (2012) microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 27(6):1967–1975PubMed

58.

Zhou Y et al. (2013) MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 47(5):423–432CrossRefPubMed

59.

Luo, Y., et al., microRNA-137 is downregulated in thyroid cancer and inhibits proliferation and invasion by targeting EGFR. Tumour Biol, 2015.

60.

Kim J et al. (2014) microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res 74(5):1541–1553CrossRefPubMedPubMedCentral

61.

Walter BA et al. (2013) Comprehensive microRNA profiling of prostate cancer. J Cancer 4(5):350–357CrossRefPubMedPubMedCentral

62.

Zhang B et al. (2015) microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18. Int J Biol Macromol 74:111–118CrossRefPubMed

63.

McBeth, L., et al., Glucocorticoid receptor beta increases migration of human bladder cancer cells. Oncotarget, 2016.

64.

Stechschulte LA et al. (2014) Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem 289(25):17885–17894CrossRefPubMedPubMedCentral

65.

Webster RJ et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284(9):5731–5741CrossRefPubMed

66.

Kefas B et al. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68(10):3566–3572CrossRefPubMed

67.

Li X, Carthew RW (2005) A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the drosophila eye. Cell 123(7):1267–1277CrossRefPubMed

68.

Tong AW et al. (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16(3):206–216PubMed

69.

Wang L et al. (2013) MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer 13:448CrossRefPubMedPubMedCentral

70.

Spahn M et al. (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127(2):394–403PubMed

71.

Teixeira AL, Gomes M, Medeiros R (2012) EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front Genet 3:286CrossRefPubMedPubMedCentral

72.

Srivastava A et al. (2013) MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One 8(10):e76994CrossRefPubMedPubMedCentral

73.

Theodore SC et al. (2010) MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Ethn Dis 20(1 Suppl 1):S1-96–S1100

74.

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866CrossRefPubMed

75.

Theodore SC et al. (2014) MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget 5(11):3512–3525CrossRefPubMedPubMedCentral

Title: Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling
Authors: Assumpta C. Nwaneri
Lucien McBeth
Terry D. Hinds Jr
Publication date: 01-12-2016
Publisher: Springer US
Published in: Discover Oncology / Issue 5-6/2016
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-016-0271-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2016

Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma

Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells

Development of Metabolic Syndrome Associated to Cancer Therapy: Review

Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network

Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice

Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page